Nadim Ahmed
Directeur Général chez CULLINAN THERAPEUTICS, INC.
Fortune : 457 817 $ au 30/06/2024
Profil
Nadim Ahmed is currently the President, Chief Executive Officer & Director at Cullinan Pearl Corp., as well as the President, Chief Executive Officer & Director at Cullinan Mica Corp.
(Massachussetts), and the President, Chief Executive Officer & Director at Cullinan Therapeutics, Inc. He is also the Director at Family Promise.
In his former positions, Mr. Ahmed served as the President, Chief Executive Officer & Director at Cullinan Oncology LLC.
He was also the Senior Marketing Director-Hematologic Oncology at GlaxoSmithKline LLC from 1998 to 2010.
From 2019 to 2021, he held the position of President-Hematology at Bristol Myers Squibb Co. Additionally, from 2010 to 2019, he was the President-Global Hematology & Oncology at Celgene Corp.Mr. Ahmed completed his undergraduate degree at University College London and his graduate degree at Loughborough University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 29/04/2024 | 26 251 ( 0,05% ) | 457 817 $ | 30/06/2024 |
Postes actifs de Nadim Ahmed
| Sociétés | Poste | Début |
|---|---|---|
| CULLINAN THERAPEUTICS, INC. | Directeur Général | 18/10/2021 |
Family Promise
 Family Promise Miscellaneous Commercial ServicesCommercial Services Family Promise is a national movement that aims to provide every family with a home, livelihood, and the opportunity to build a better future. The non-profit company is based in Summit, NJ. The organization works in over 200 communities across 43 states to ensure that families experiencing or at risk of homelessness have a safe place to call home. Family Promise delivers innovative solutions for family homelessness, including prevention, shelter, and stabilization services. Family Promise aspires to change the future for 1 million children by 2030 through its community-based programs. The organization was founded more than 30 years ago as a local initiative in Summit, NJ, and has since served over 1 million family members. | Directeur/Membre du Conseil | - |
Cullinan Pearl Corp.
 Cullinan Pearl Corp. BiotechnologyHealth Technology Part of Otsuka Holdings Co., Ltd., Cullinan Pearl Corp. is a company that develops an orally available tyrosine kinase inhibitor. The company is based in Cambridge, MA. The CEO of the company is Nadim Ahmed. Cullinan Pearl was acquired by Taiho Pharmaceutical Co., Ltd. from Cullinan Oncology, Inc. on June 23, 2022 for $405 million. | Directeur Général | - |
Cullinan Mica Corp.
 Cullinan Mica Corp. Pharmaceuticals: MajorHealth Technology Part of Cullinan Therapeutics, Inc., Cullinan Mica Corp. is a company that provides worldwide rights to CLN-619. The company is based in Cambridge, MA. The CEO of the company is Nadim Ahmed. | Directeur Général | - |
Anciens postes connus de Nadim Ahmed
| Sociétés | Poste | Fin |
|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01/01/2021 |
| CELGENE | Corporate Officer/Principal | 01/11/2019 |
GlaxoSmithKline LLC
 GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology GlaxoSmithKline LLC engages in discovering, developing, and delivering medicines, vaccines, and other healthcare products. It offers prescription medicines that treat various diseases, including cancer, HIV/AIDS, depression, diabetes, high blood pressure, herpes, asthma, migraine, and heart diseases, as well as stomach and skin problems, infections, and flu. It also provides vaccines for children and adults; and over-the-counter products. The company was founded in 1929 and is headquartered in Philadelphia, PA. | Corporate Officer/Principal | 01/03/2010 |
Cullinan Oncology LLC
 Cullinan Oncology LLC Financial ConglomeratesFinance Cullinan Oncology LLC is a biopharmaceutical company, which engages in the development of a pipeline of targeted oncology and immuno-oncology therapies for cancer diseases. The company was founded by Patrick Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA. | Directeur Général | - |
Formation de Nadim Ahmed
| University College London | Undergraduate Degree |
| Loughborough University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| CULLINAN THERAPEUTICS, INC. | Health Technology |
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| Entreprise privées | 6 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
Family Promise
Family Promise Miscellaneous Commercial ServicesCommercial Services Family Promise is a national movement that aims to provide every family with a home, livelihood, and the opportunity to build a better future. The non-profit company is based in Summit, NJ. The organization works in over 200 communities across 43 states to ensure that families experiencing or at risk of homelessness have a safe place to call home. Family Promise delivers innovative solutions for family homelessness, including prevention, shelter, and stabilization services. Family Promise aspires to change the future for 1 million children by 2030 through its community-based programs. The organization was founded more than 30 years ago as a local initiative in Summit, NJ, and has since served over 1 million family members. | Commercial Services |
Cullinan Oncology LLC
Cullinan Oncology LLC Financial ConglomeratesFinance Cullinan Oncology LLC is a biopharmaceutical company, which engages in the development of a pipeline of targeted oncology and immuno-oncology therapies for cancer diseases. The company was founded by Patrick Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA. | Finance |
Cullinan Pearl Corp.
Cullinan Pearl Corp. BiotechnologyHealth Technology Part of Otsuka Holdings Co., Ltd., Cullinan Pearl Corp. is a company that develops an orally available tyrosine kinase inhibitor. The company is based in Cambridge, MA. The CEO of the company is Nadim Ahmed. Cullinan Pearl was acquired by Taiho Pharmaceutical Co., Ltd. from Cullinan Oncology, Inc. on June 23, 2022 for $405 million. | Health Technology |
GlaxoSmithKline LLC
GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology GlaxoSmithKline LLC engages in discovering, developing, and delivering medicines, vaccines, and other healthcare products. It offers prescription medicines that treat various diseases, including cancer, HIV/AIDS, depression, diabetes, high blood pressure, herpes, asthma, migraine, and heart diseases, as well as stomach and skin problems, infections, and flu. It also provides vaccines for children and adults; and over-the-counter products. The company was founded in 1929 and is headquartered in Philadelphia, PA. | Health Technology |
Cullinan Mica Corp.
Cullinan Mica Corp. Pharmaceuticals: MajorHealth Technology Part of Cullinan Therapeutics, Inc., Cullinan Mica Corp. is a company that provides worldwide rights to CLN-619. The company is based in Cambridge, MA. The CEO of the company is Nadim Ahmed. | Health Technology |
